Radiotheranostics & Precision Medicine Innovation Core

Introduction

This research core is dedicated to advancing the emergence of precision medicine grounded in radiopharmaceutical science.

Building upon Okayama University’s internationally recognized achievements and strengths established through regional industry–academia–government collaboration initiatives, the core promotes radiopharmaceutical-based drug discovery and the development of advanced imaging technologies, with a central focus on theranostics, which integrates diagnosis and therapy.

By visualizing disease processes at the molecular level and translating these insights into optimized treatments for individual patients, the core serves as a central hub for next-generation medical innovation.

Research Overview

1. Development of 18F-Labeled PET Imaging Agents.

We develop high-performance PET tracers labeled with 18F and other positron-emitting radionuclides, including small molecules, peptides, antibodies, and nanoparticle-based probes, enabling precise molecular visualization of disease.

2. Radiopharmaceutical Design and Optimization Platform.

We establish advanced platforms for molecular engineering, radiolabeling chemistry, and pharmacokinetic optimization to enhance target specificity and in vivo performance of imaging and therapeutic agents.

3. Targeted Radiotherapeutics.

We develop therapeutic radiopharmaceuticals incorporating beta- and alpha-emitting radionuclides to achieve precise and effective targeted radiotherapy.

4. Theranostic Integration and Personalized Dosimetry.

By integrating diagnostic and therapeutic isotopes, we design patient-specific treatment strategies guided by imaging biomarkers and quantitative dosimetric analysis.

5. Translational Advancement and Clinical Implementation.

We promote seamless translation from preclinical validation to clinical application, accelerating the development of next-generation radiopharmaceuticals from bench to bedside.